According to @StockMarketNerd, NVDA’s last five years of profit growth have been exceptionally strong at massive scale, highlighting sustained operating momentum traders track for positioning (source: @StockMarketNerd on X, Nov 19, 2025). NVIDIA’s filings attribute multi-year expansion primarily to accelerated computing and generative AI demand that lifted data center sales and profitability metrics (source: NVIDIA FY2024 Form 10-K, NVIDIA Investor Relations). The company reported record total revenue and record data center revenue in FY2024, reinforcing the profitability uptrend cited by the author and providing concrete inputs for earnings-revision and margin-trend analysis (source: NVIDIA FY2024 earnings materials, NVIDIA Investor Relations). NVIDIA also launched Cryptocurrency Mining Processor (CMP) products in 2021 to serve miners, underscoring the linkage between GPU cycles and crypto-mining hardware demand that crypto-focused traders may monitor when assessing GPU supply dynamics (source: NVIDIA Blog, NVIDIA Introducing Cryptocurrency Mining Processor (CMP), Feb 2021). Traders can verify segment growth, capex-driven demand signals, and supply commentary in recent earnings releases and the FY2024 10-K to calibrate NVDA equity and options exposure with objective data (source: NVIDIA Investor Relations).

According to @StockMKTNewz, Eli Lilly (LLY) and Nvidia (NVDA) announced a partnership to build what the companies describe as the most powerful supercomputer run by a pharmaceutical company to boost the discovery of new medicines, as reported in The Wall Street Journal via the cited post. Source: @StockMKTNewz post on X dated Oct 28, 2025; The Wall Street Journal as cited by @StockMKTNewz. This headline establishes a tangible AI-compute catalyst tied to drug discovery workflows for both LLY and NVDA, with the core claim being the build-out of the most powerful pharma-run supercomputer and its stated aim to accelerate medicine discovery. Source: @StockMKTNewz post on X dated Oct 28, 2025; The Wall Street Journal as cited by @StockMKTNewz. No additional specifications, capex details, or deployment timelines were provided in the cited post beyond the claim of building the most powerful pharma-operated supercomputer for boosting drug discovery. Source: @StockMKTNewz post on X dated Oct 28, 2025.